You are here

Article Text

Article menu

Download PDFPDF

Poster/ePoster Sessions
09. Prevention of Gynaecologic Cancer
#785 HPV and istanbul, an interpretation of the HPV screening implemented by The National Health Ministry
Free
  1. Abdullah Emre Güner1,
  2. Soner Sabirli2,
  3. Seniz Kavak3,
  4. Kemal Kural3,
  5. Atilla Kunt4 and
  6. Ates Karateke5
  1. 1Department of Public Health, University of Health Sciences Faculty of Medicine, Istanbul, Türkiye
  2. 2Department of Pharmacology, University of Health Sciences Faculty of Medicine, Istanbul, Istanbul, Türkiye
  3. 3Public Health Services, Istanbul Health Directorate, Istanbul, Türkiye
  4. 4Department of Obstetrics and Gynecology, Istanbul Medeniyet University, Istanbul, Türkiye
  5. 5Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Istanbul Medeniyet University, Istanbul, Türkiye

Abstract

Introduction/Background Screening for HPV is essential because it can detect the virus before it causes any symptoms or leads to the development of cancer. HPV screening is crucial in detecting HPV infections before they lead to the development of cancer and reducing the incidence and mortality of HPV-related cancers. In this study we analysed HPV Screening data between 2015 and 2020

Methodology In 2012 Turkish Ministry of Health started the screening program, and implemented HPV testing as the primary method for cervical cancer screening. In 2014 centralized HPV testing laboratories started to serve in Ankara and Istanbul. In order to achieve adequate coverage of population, screening procedures started to be performed by family health centers also all other government institutions. Cervical cancer screenings are performed in women the ages of 30–65 years. The interval for screening is 5 years. Two cervical specimens are collected simultaneously during the procedure, one for HPV isolation and sub-typing and one for the reflex cytologic evaluation if needed. Data gathered from National Health Ministry and HPVDNA data between 2015 and 2020 and the data was evaluated.

Results The HPV DNA positivity rate increased from 4.29% in 2015 to 8.9 in 2020. During the COVID-19 pandemic, many healthcare resources were diverted towards managing and treating COVID-19 patients, leading to a reduction in routine health services, including cervical cancer screening. Majority (54,59%) of HPV positive individuals in screening population were infected with more than one HPV subtypes. Most common subtypes were HPV16 (16.52%), HPV51 (8.17%), HPV31 (7.55%), HPV52 (6.08%),HPV66 (5.24%) These findings remained consistent within each age groups.

View this table:
Abstract #785 Table 1

Year distribution of screening numbers and HPV screening results across years

Conclusion With improved testing and the increasing population if immigrants in Istanbul, we believe that HPV screening and preventative measures such as vaccinations are more important that ever in screening HPV and preventing cervical cancer.

Disclosures There are no known conflict of interest among the authors.

http://dx.doi.org/10.1136/ijgc-2023-ESGO.736

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.